Home Cart Sign in  
Chemical Structure| 2835-95-2 Chemical Structure| 2835-95-2

Structure of 2835-95-2

Chemical Structure| 2835-95-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 2835-95-2 ]

CAS No. :2835-95-2
Formula : C7H9NO
M.W : 123.15
SMILES Code : C1=C(N)C=CC(=C1O)C
MDL No. :MFCD00043922
InChI Key :DBFYESDCPWWCHN-UHFFFAOYSA-N
Pubchem ID :17818

Safety of [ 2835-95-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H303
Precautionary Statements:P264-P280-P302+P352-P312-P337+P313-P305+P351+P338-P362+P364-P332+P313

Computational Chemistry of [ 2835-95-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 6
Fraction Csp3 0.14
Num. rotatable bonds 0
Num. H-bond acceptors 1.0
Num. H-bond donors 2.0
Molar Refractivity 37.84
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

46.25 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.21
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.32
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.29
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.15
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.11
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.22

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.93
Solubility 1.45 mg/ml ; 0.0118 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.89
Solubility 1.58 mg/ml ; 0.0128 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.8
Solubility 1.93 mg/ml ; 0.0157 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.11 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.0

Application In Synthesis of [ 2835-95-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 2835-95-2 ]

[ 2835-95-2 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 2835-95-2 ]
  • [ 36138-76-8 ]
YieldReaction ConditionsOperation in experiment
26% To a solution of 5-AMINO-2-METHYLPHENOL (10 G, 81.2 MMOL) in hydrobromic acid (40 mL, 48 % solution) and water (50 mL) at 0 C was added a solution of sodium nitrite (5.6 g, 81.2 MMOL) in water (15 mL) and the mixture stirred at this temperature for 30 minutes. To this was added copper (I) bromide (11.6 G, 81. 2 MMOL) in hydrobromic acid (15 mL, 48% solution) and the reaction was subsequently heated at reflux for 2 hours. Upon cooling to room temperature the resulting mixture was extracted with ethyl acetate (2 x 200 mL) and the combined organic extracts were washed with aqueous potassium hydroxide solution (-1 M, 200 mL), dried (magnesium sulphate) and concentrated under reduced pressure. The crude product was purified by column chromatography [SI02 ; light petroleum to 4: 1 light petroleum-ethyl acetate] to give the title compound as a COLOURLESS OIL, WHICH CRYSTALLISED to give fine colourless needles upon standing overnight (4 G, 26 %). Rf = 0.26 [4: 1 light petroleum-ethyl acetate]. 1H NMR 5 2.21 (3 H, s), 4.89-4. 95 (1 H, br, s), 6.96-6. 97 (1 H, br, m), 6.99-7. 00 (2 H, m).
24% To a solution of 5-amino-2-methylphenol (50 g, 0.41 mol) in hydrobromic acid (200 mL, 48 % solution) and water (200 ml) in a brine ice bath was added sodium nitrite (30.5 g, 0.45 mol, 1.1 equiv.) portion-wise at such a rate that the temperature remained below +10 C, and the mixture was stirred for a EPO <DP n="68"/>further 15 minutes. To this solution was added copper(l) bromide (64 g, 0.44 mol, 1.1 equiv.) and the reaction was subsequently heated to 80 0C. Effervescence was observed at 60-65 C indicating that the reaction had occurred. The mixture was heated at 80 C for a further 30 minutes and then allowed to cool to room temperature. The resulting black tarry mixture was extracted with petroleum ether 40-60 0C (4 x 400 ml) and the combined organic extracts were dried (MgSO4) and concentrated under reduced pressure. [Note that a large tarry component does not dissolve in either petrol or the aqueous layer and sometimes the petrol layer was simply decanted from this once all the aqueous layer had been run out from the separating funnel]. The resulting orange-white solid was recrystallised from petrol to give the product as a white solid (13 g 17 %). The mother liquors were further purified by dry flash column chromatography (particle size 3-35 A), eluting with 0-20% diethyl ether in petroleum ether 40-60 0C to give a yellow-white crystalline solid which was re-crystallised from petroleum ether 40-60 C to give a further 5 g and an overall yield of 18 g (24 %); Rf = 0.26 (4:1 petrol- ethyl acetate), m.p. 77-78 C (from petrol). 1H NMR deltaH 2.21 (3 H, s), 4.89- 4.95 (1 H, br, s), 6.96-6.97 (1 H, br, m) and 6.99-7.00 (2 H, m).
20% Example 60; Synthesis of 4-(4-methyl-3-(5-(trifluoromethyl)pyridin-2-yloxy)benzylidene)-N-(pyridin-3-yl)piperidine-1-carboxamide; Step 1; 5-Bromo-2-methylphenol; 5-Amino-2-methylphenol (5 g, 0.04 mol) was dissolved in HBr (20 mL) and H2O (20 mL) was added dropwise maintaining a temperature below 0 C. The resulting mixture was stirred for 5 min and a solution of NaNO2 (2.76 g, 0.04 mol) in H2O (7.5 mL) was added dropwise. The mixture was stirred for 30 min below 0 C. Then a solution of cuprous bromide (5.73 g, 0.04 mol) in HBr (7.5 mL) cooled to 0 C. was added dropwise. The resulting mixture was warmed to RT and then refluxed for 2 h. The reaction was cooled and filtered through celite. The filtrate was diluted with water and extracted with EtOAc. The organic extract was dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (2.5% EtOAc-97.5% Hexane) to give the pure title compound (1.57 g, 20%). 1H NMR (500 MHz, CDCl3): delta 6.97 (s, 3H), 4.89 (s, 1H), 2.19 (s, 3H).
  • 2
  • [ 2835-95-2 ]
  • [ 214476-78-5 ]
  • 4-(3-hydroxy-4-methyl-phenylamino)-8-methoxy-quinoline-3-carbonitrile [ No CAS ]
YieldReaction ConditionsOperation in experiment
With pyridine hydrochloride; In 2-ethoxy-ethanol; EXAMPLE 276 4-(3-Hydroxy-4-methyl-phenylamino)-8-methoxy-quinoline-3-carbonitrile Using an analogous procedure to that described in Example 274. A reaction mixture of 328.0 mg (1.5 mmol) of 4-chloro-8-methoxy -3-quinolinecarbonitrile, 173.3 mg (1.5 mmol) of pyridine hydrochloride and 203.2 mg (1.7 mmol) of 3-hydroxy-4-methyl-aniline in 15 mL of 2-ethoxyethanol was heated at 100 C. for 1.5 hr. After the work up, 407.7 mg (89.4%) of the product was obtained as a yellow solid, m.p. 148-150 C., mass spectrum (electrospray, m/e): M+H 306.9.
With pyridine hydrochloride; In 2-ethoxy-ethanol; EXAMPLE 276 4-(3-Hydroxy-4-methyl-phenylamino)-8-methoxy-quinoline-3-carbonitrile Using an analogous procedure to that described in Example 274. A reaction mixture of 328.0 mg (1.5 mmol) of 4-chloro-8-methoxy -3-quinolinecarbonitrile, 173.3 mg (1.5 mmol) of pyridine hydrochloride and 203.2 mg (1.7 mmol) of 3-hydroxy-4-methylaniline in 15 mL of 2-ethoxyethanol was heated at 100 C. for 1.5 hr. After the work up, 407.7 mg (89.4%) of the product was obtained as a yellow solid, m.p. 148-150 C., mass spectrum (electrospray, m/e): M+H 306.9.
With pyridine hydrochloride; In 2-ethoxy-ethanol; Example 276 4-(3-Hydroxy-4-methyl-phenylamino)-8-methoxy-quinoline-3-carbonitrile Using an analogous procedure to that described in Example 274. A reaction mixture of 328.0 mg (1.5 mmol) of 4-chloro-8-methoxy -3-quinolinecarbonitrile, 173.3 mg (1.5 mmol) of pyridine hydrochloride and 203.2 mg (1.7 mmol) of 3-hydroxy-4-methylaniline in 15 mL of 2-ethoxyethanol was heated at 100 C for 1.5 hr. After the work up, 407.7 mg (89.4%) of the product was obtained as a yellow solid, m.p. 148-150C, mass spectrum (electrospray, m/e): M+H 306.9.
  • 3
  • [ 24424-99-5 ]
  • [ 2835-95-2 ]
  • [ 345893-26-7 ]
YieldReaction ConditionsOperation in experiment
18% With triethylamine; In tetrahydrofuran; at 0 - 20℃; for 15h; Reference Example 32; tert-butyl (3-hydroxy-4-methylphenyl) carbamate; To a solution of 5-amino-2-methylphenol (10.0 g, 81.2 mmol) and triethylamine (16.9 rtiL, 122 mmol) in tetrahydrofuran (75 mL) was added dropwise with stirring under ice-cooling a solution of di-tert-butyl-dicarbonate (19.5 g, 89.3 mmol) in tetrahydrofuran(25 mL) , and the mixture was stirred at room temperature for 15 hr. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and filtrated. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate =95/5->50/50) to give the title compound (3.25 g, 18%) as a colorless oil.1H-NMR (DMSOd6, 300 MHz) delta 1.46 (9H, s) , 2.02 (3H, s) , 6.71 (IH, dd, J = 8.2, 1.8 Hz), 6.87 (IH, d, J = 8.2 Hz), 7.07 (IH, d, J = 1.8 Hz), 9.09 (IH, s) , 9.16 (IH, s) .
 

Historical Records

Technical Information

Categories